ID   BxPC3-R
AC   CVCL_XX78
DR   cancercelllines; CVCL_XX78
DR   GEO; GSM1906994
DR   GEO; GSM1906995
DR   GEO; GSM1906996
DR   Wikidata; Q93433506
RX   PubMed=27229158;
RX   PubMed=27910856;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0186 ! BxPC-3
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=27229158; DOI=10.1038/cgt.2016.23;
RA   Schreiber R., Mezencev R., Matyunina L.V., McDonald J.F.;
RT   "Evidence for the role of microRNA 374b in acquired cisplatin
RT   resistance in pancreatic cancer cells.";
RL   Cancer Gene Ther. 23:241-245(2016).
//
RX   PubMed=27910856; DOI=10.1038/cgt.2016.71;
RA   Mezencev R., Matyunina L.V., Wagner G.T., McDonald J.F.;
RT   "Acquired resistance of pancreatic cancer cells to cisplatin is
RT   multifactorial with cell context-dependent involvement of resistance
RT   genes.";
RL   Cancer Gene Ther. 23:446-453(2016).
//